key: cord-0734102-hth04fop authors: Holtz, Ben‐Ole; Grimm, Alexander; Axer, Hubertus title: Patients' attitude towards vaccination after Guillain Barré syndrome date: 2021-12-21 journal: Health Sci Rep DOI: 10.1002/hsr2.469 sha: 979034fb7700696c7b8af9babca4a50893504a33 doc_id: 734102 cord_uid: hth04fop BACKGROUND AND AIMS: Guillain Barré syndrome (GBS) could be triggered by an infectious disease but by vaccination as well. Thus, suffering GBS may influence patients' attitudes towards vaccination. METHODS: An anonymous questionnaire consisting of the Overall Neuropathy Limitations Score (ONLS), the short form‐36 health survey (SF‐36), and questions addressing patients' attitude towards vaccination was sent to members of a German GBS support group and to patients with GBS diagnosis who were treated at Jena University Hospital. RESULTS: Ninety‐seven questionnaires clearly stated GBS as a diagnosis and were included in the analysis. Although 19.6% of the GBS patients reported having no disability in the long‐time follow‐up, a considerable number of patients still had persistent neurological symptoms; 74.2% of the GBS patients reported being able to walk at least 10 m independently. However, 5.2% were restricted to wheelchair. The patients reached lower scores in all domains of quality of life compared to German controls. Moreover, patients showed a more critical attitude towards vaccination compared to a German representative survey. Fewer patients (58.8%) received a vaccination after suffering from GBS than before (77.3%). Every tenth patient believed that vaccination was the trigger for the GBS. 32% of the patients did not receive a vaccination in the last 5 years mainly because of the fear of adverse effects (32%) or disadvise of the general practitioners (25.8%). DISCUSSION: Although the risk of relapse following immunization may be rather low, uncertainties and fears still impair the counseling of these patients by their medical practitioner. immunoglobulin are proven effective treatments for GBS. 5 About 25% of patients develop respiratory insufficiency, 6 and many show signs of autonomic dysfunction 7 that mainly demands intensive care treatment. GBS is typically triggered by an infectious disease and may be associated with various pathogens (eg, campylobacter jejuni, cytomegalovirus, Epstein-Barr virus, mycoplasma pneumonia, haemophilus influenzae, influenza A virus, and others). In addition, GBS was also found in patients with COVID-19, [8] [9] [10] [11] but also influenza vaccination, trauma, surgical intervention, and others may be a potential trigger to develop GBS. Functional outcome is associated with the amount of axonal damage. [12] [13] [14] Incomplete recovery is mainly caused by residual neuropathy affecting various parts of the peripheral nervous system after the acute phase of GBS, 15 and therefore, may cause significant impairment of quality of life. 16 However, functional recovery may be heterogeneous due to heterogeneity in pathophysiology, severity, duration of the disease, beginning of treatment, and individual comorbidities of the patients. In addition, GBS has been generally considered to be a vaccine-associated adverse event 17 18 In addition, a meta-analysis 19 based on six adverse event monitoring systems with about 23 million vaccinated people showed that Influenza A (H1N1) 2009 vaccines were associated with a small increased risk of GBS. However, at the end of the 2009 pandemic, the cumulative GBS risk was less among the pH1N1vaccinated than the unvaccinated population, rather suggesting a benefit of vaccination as it relates to GBS. 20 Nevertheless, patients may fear potential recurrences of GBS following vaccination, 21 which, in turn, may influence patients' behavior and attitude relating to vaccination and introduce uncertainties in the counseling of these patients by the general practitioner. This becomes increasingly relevant in the focus of actual COVID-19 vaccination programs, although COVID vaccination was not available at the timepoint of this survey. Here, we performed a survey focusing on the attitude towards vaccination of patients after suffering from GBS. An anonymous questionnaire was designed, which included the following subsets: General information of the patients were collected (age, gender, year of the disease onset, diagnosis). Questions relating to the attitude towards vaccination were partly taken from a German representative survey of prevention of infection, 22 which is an opinion survey of 5054 interviewees to attitude, knowledge, and behavior regarding vaccination. In addition, some GBS-specific questions were designed to evaluate a possible influence of the GBS towards the attitude concerning vaccination. The questions used in the questionnaire are collected in Table 1 . For evaluating the disability of the patients due to neuropathic symptoms, the ONLS (Overall Neuropathy Limitations Score) was used. 23 The ONLS is a scale that measures limitations in the everyday activities of the upper and lower limbs, and therefore, focuses on daily relevant activities. It is validated as an observed measure by clinicians watching patients perform the tasks. 23 In this study, the patients were asked to evaluate their abilities by themselves or by their relatives. Quality of life was evaluated using the short form-36 health survey (SF-36). 24, 25 The SF-36 is a validated patient-reported survey of patient health and comprises eight domains (physical functioning, role physical, bodily pain, general health perception, vitality, social functioning, role emotional, mental health). All statistical analyses were performed using SPSS 27.0 (SPSS Inc., Chicago, IL, USA). Differences in self-reported features between groups were calculated using the t-test with a two-sided significance level of P < .05%. Missing values in the SF-36 questionnaire were substituted with person-specific estimates if the respondent answered at least 50% of the items in a domain according to the half-scale rule from the SF-36 developers. 26 The raw data of the SF-36 were transformed to z-scores based on a German normative sample. 24 A zscore describes the position of a raw score in terms of its distance from the mean when measured in SD units. The z-score is positive if the value lies above the mean and negative if it lies below the mean. Totally 130 patients filled out and returned the questionnaires, but only in 97 questionnaires, GBS was clearly stated as a diagnosis and could finally be included in the analysis. CIDP was stated in 26 cases as diagnosis, and 7 did not state a diagnosis at all so that these questionnaires were excluded from the analysis. The basic characteristics of the patients can be seen in Table 2 . Totally 77.3% (n = 75) received a vaccination before suffering from GBS, but only 58.8% (n = 57) were vaccinated after GBS. 11.3% (n = 11) believe that a vaccination has triggered the GBS and 38.1% (n = 37) reported to be anxious that a vaccination may trigger a recurrence of the GBS. Compared to the results of the German representative study, 22 where 5054 people were interviewed for attitude, knowledge, and behavior with regard to vaccination, the GBS patients of our study showed a more critical attitude towards vaccination ( Figure 1 ); 25% of the GBS patients reported being deprecatory or rather deprecatory against vaccination. Comparing the patients from the self-help group with the former hospital patients showed a significant difference (Chi-square test, P = .043) implying that the patients from the self-help group showed the most critical attitude against vaccination (34% vs 15% deprecatory or rather deprecatory). Further results are shown in Figure 2 . Of the GBS patients, 36.1% (n = 35) reported having taken advice regarding vaccination in the last 2 years; 68% have been vaccinated in the last 5 years, in most cases, against tetanus or seasonal flu. There was no correlation with age (Table 3 ). Regional differences were not collected and could not be analyzed. Table 3 gives an overview of the 12.5% reported a total score larger than 5 with rather significant disability. All patients scored lower in all items of the SF-36 when compared with the normal German population. 24 No statistically significant differences (t-test) in the SF-36 scores were detected between patients from the support group and the former patients of the university hospital. Figure 3B shows the results of the SF-36 survey. The ONLS score showed the highest Pearson correlation coefficients to physical functioning (À0.689, P < .001) and role physical (À0.595, P < .001). The semiquantitative scores for the attitude towards vaccination were weakly correlated to the ONLS score (Pearson correlation 0.219, F I G U R E 2 Additional questions regarding patients' attitude towards vaccination P = .33, Figure 4 ), while no significance was found for a correlation to age or the SF-36 scores. In contrast, large epidemiological studies have shown that GBS rates after the influenza vaccine have been less than one case per million vaccinated people. 27 In addition, influenza vaccine-induced relapse of GBS also is evaluated as to be extremely seldom, so that prior GBS should not preclude influenza vaccination. 28 Even the risk of developing a GBS relapse is very low after mRNA COVID-19 vaccine application. 29 Thus, it can be concluded that also post-GBS patients can be vaccinated safely. It has been stated that the risk of GBS is 4-7 times higher after influenza infection than after influenza vaccine. 32 Less than 1 case of GBS per million immunized persons might occur for these vaccines. 33 Weighing up the hypothesized risks of adverse events, such as GBS, and the beneficial effects of vaccination, it can be argued that the potential risk to develop GBS cannot be considered a valid reason to avoid the administration of currently recommended vaccines. 33 A major concern is that vaccination may trigger a relapse of GBS. Recently, a large population-based nested case-control study found no evidence that demonstrated an association of vaccines with an increased risk of GBS and its recurrence within the 180 days following Our study was partly based on questionnaires sent to patients who are members of a patient organization, which makes this study susceptible to recall and selection bias. However, no statistically significant differences have been found (t-test) between patients contacted via patient organization (n = 71) and patients who were treated at Jena University Hospital (n = 48) neither in ONLS scores nor in SF-36 scores. However, the patients from the self-help group showed a more critical attitude towards vaccinations compared to the former hospital patients. The questionnaires were sent to more than 800 persons, but less than 100 could be included in this study. This has led to a selection bias towards possibly more severe cases with unfavorable outcomes as the reported outcomes were more severe than in many of the population-based outcome studies cited above. Thus, it has to be kept in mind that the data represent the attitude in a very selective group of patients. No funding. None of the authors has any conflict of interest to disclose. Hubertus Axer has full access to all the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis. We confirm that this manuscript is an honest, accurate, and transparent account of the study being reported, no important aspects of the study have been omitted, and all discrepancies from the study as planned have been explained. The data that support the findings of this study are available from the corresponding author upon reasonable request. ORCID Guillain-Barré syndrome Guillain-Barre Syndrome Diagnosis and management of Guillain-Barré syndrome in ten steps The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review Current treatment practice of Guillain-Barré syndrome Outcomes for patients with Guillain-Barré syndrome requiring mechanical ventilation: a literature review Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis Neurological associations of COVID-19 Guillain-Barré syndrome related to COVID-19 infection Guillain-Barré Syndrome Associated with SARS-CoV-2 Could symptom overlap of COVID-19 and Guillain-Barré syndrome mask an epidemiological association? Axonal variants of Guillain-Barré syndrome: an update The long-term prognosis of Guillain-Barré syndrome. Evaluation of prognostic factors, including plasma exchange CSF neurofilament levels: a potential prognostic marker in Guillain-Barré syndrome Residual neuropathy in longterm population-based follow-up of Guillain-Barré syndrome The long-term functional status in patients with Guillain-Barré syndrome Is an increased risk of developing Guillain-Barré syndrome associated with seasonal influenza vaccination? a systematic review and meta-analysis Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977 Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis Cumulative risk of Guillain-Barré syndrome among vaccinated and unvaccinated populations during the 2009 H1N1 influenza pandemic Recurrences, vaccinations and long-term symptoms in GBS and CIDP Wissen Und Verhalten von Erwachsenen Und Eltern Gegenüber Impfungen -Ergebnisse Der Repräsentativbefragung A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale SF-36 -Deutsche Version Des Short Form-36 Health Survey: Manual SF-36 Health Survey: Manual and Interpretation Guide User's Manual for the SF-36v2 Health Survey Guillain-Barré syndrome after exposure to influenza virus Influenza vaccine and the risk of relapse of Guillain-Barré syndrome Rate of recurrent Guillain-Barré syndrome after mRNA COVID-19 vaccine BNT162b2 Reflections on New York City's 1947 Smallpox Vaccination Program and Its 1976 Swine Influenza Immunization Program Guillain-Barré syndrome and influenza vaccines: a meta-analysis Influenza vaccine, Guillain-Barré syndrome, and chasing zero Vaccine-preventable diseases, vaccines and Guillain-Barre' syndrome Vaccines and the risk of Guillain-Barré syndrome Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation Recurrent Guillain-Barre syndrome following vaccination Post-infectious Guillain-Barré syndrome related to SARS-CoV-2 infection: a systematic review COVID-19-associated Guillain-Barre syndrome: postinfectious alone or neuroinvasive too Guillain-Barré Syndrome following ChAdOx1-S/nCoV-19 vaccine Case of Guillain-Barré syndrome following COVID-19 vaccine Exacerbating Guillain-Barré syndrome eight days after vector-based COVID-19 vaccination Neurological complications of COVID-19: Guillain-Barre syndrome following pfizer COVID-19 vaccine Emerging infection, vaccination, and Guillain-Barré syndrome: a review Regional variation of Guillain-Barré syndrome Long-term outcome in patients with Guillain-Barré syndrome requiring mechanical ventilation Long-term prognosis for Guillain-Barré syndrome: evaluation of prognostic factors and clinical experience of automated double filtration plasmapheresis Piemonte and Valle d'Aosta Register for Guillain-Barré Syndrome. Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey Recovery patterns and long term prognosis for axonal Guillain-Barré syndrome The morbidity and outcome of patients with Guillain-Barré syndrome admitted to the intensive care unit Inflammatory Neuropathy Cause and Treatment (INCAT) group. Quality of life complements traditional outcome measures in immune-mediated polyneuropathies Six-month prospective study of quality of life in Guillain-Barre syndrome Disability and quality of life in Guillain-Barré syndrome -Longitudinal study Long-term outcome in patients with Guillain-Barré syndrome requiring mechanical ventilation Clinical outcome of Guillain-Barré syndrome after prolonged mechanical ventilation Three-year follow-up study in patients with Guillain-Barré syndrome Long-term outcome of Guillain-Barré syndrome Long term disability and social status change after Guillain-Barré syndrome How to cite this article: Holtz B-O, Grimm A, Axer H. Patients' attitude towards vaccination after Guillain Barré syndrome https://orcid.org/0000-0002-8615-5040Hubertus Axer https://orcid.org/0000-0002-3191-2796